Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actos Sales Grow On Avandia’s Woes, Takeda Reports

This article was originally published in The Pink Sheet Daily

Executive Summary

U.S. sales of the diabetes therapy pioglitazone were up 19.2 percent year over year, Takeda reports.

You may also be interested in...



Benefits Of Avandia, Actos Outweigh Risks – EMEA

EMEA panel recommends additional warnings for rosiglitazone products, but gives positive opinion on continued marketing.

Benefits Of Avandia, Actos Outweigh Risks – EMEA

EMEA panel recommends additional warnings for rosiglitazone products, but gives positive opinion on continued marketing.

FDA Says GlaxoSmithKline’s Advair 500/50 “Not Approvable” For COPD

Agency questions efficacy of COPD treatment over lower strength; GSK tells “The Pink Sheet” DAILY that head-to-head trials were not conducted.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel